Brief: Lantern Pharma Receives Taiwan Approvals To Open Next Stage Of Phase 2 Harmonic Trial Of Lp-300 In Never-Smoker, Egfr-Mutant Nsclc
07/10/2026 13:48
BRIEF-Lantern Pharma Receives Taiwan Approvals To Open Next Stage Of Phase 2 Harmonic Trial Of Lp-300 In Never-Smoker, Egfr-Mutant Nsclc Oct 7 (Reuters) - Lantern Pharma Inc LTRN.O:
LANTERN PHARMA RECEIVES TAIWAN APPROVALS TO OPEN NEXT STAGE OF PHASE 2 HARMONIC™ TRIAL OF LP-300 IN NEVER-SMOKER, EGFR-MUTANT NSCLC
LANTERN PHARMA - PLANS TO OPEN ADDITIONAL SITES IN TAIWAN FOR PART 2 ENROLLMENT
Source text: ID:nBwwz2N3a
Further company coverage: LTRN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Receives Taiwan Approvals To Open Next Stage Of Phase 2 Harmonic Trial Of Lp-300 In Never-Smoker, Egfr-Mutant Nsclc
Brief: Lantern Pharma Reports Second Quarter 2026 Financial Results And Provides Business Update
Lantern Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Lantern Pharma Q2 operating loss widens on warrant expenses tied to higher stock price
Lantern Pharma Inc expected to post a loss of 38 cents a share - Earnings Preview